Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy (vol 368, pg 138, 2013)

被引：0
|
作者：
Ryan, Charles J.
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：584 / 584
页数：1
相关论文
共 50 条
  • [21] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21): : 1995 - 2005
  • [22] Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, Susan F.
    Knudsen, Karen E.
    Halabi, Susan
    Fleming, Mark T.
    Molina, Ana M.
    Wolf, Steven Paul
    de Leeuw, Renee
    Fernandez, Celina
    Kang, Praneet
    Southwell, Traci
    Jones, Carol L.
    Fernandez, Escarleth
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] Selection Criteria for Lung-Cancer Screening (vol 368, pg 728, 2013)
    Tammemaegi, Martin C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (04): : 394 - 394
  • [24] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer (vol 18, pg 558, 2013)
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (06): : 775 - 775
  • [25] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer (vol 18, pg 558, 2013)
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (08): : 971 - 971
  • [26] Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer (vol 29, pg 243, 2012)
    Scott, L. J.
    Yang, L. P. H.
    Lyseng-Williamson, K. A.
    DRUGS & AGING, 2012, 29 (05) : 420 - 420
  • [27] A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer (vol 33, pg 333, 2017)
    Sharma, A. P.
    INDIAN JOURNAL OF UROLOGY, 2019, 35 (02) : 175 - 175
  • [28] Prognostic index for progression-free survival in metastatic castration-resistant prostate cancer patients without previous chemotherapy: An analysis of the COU-AA-302 abiraterone acetate study
    Ryan, C. J.
    Kheoh, T.
    Molina, A.
    Carles, J.
    Efstathiou, E.
    Kantoff, P. W.
    Mulders, P. F. A.
    Saad, F.
    Griffin, T.
    Chi, K. N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S683 - S684
  • [29] Re: Abiraterone and Increased Survival in Metastatic Prostate Cancer
    Richie, Jerome P.
    EUROPEAN UROLOGY, 2011, 60 (04) : 871 - 871
  • [30] Use and security analysis of abiraterone in metastatic prostate cancer
    Dolores Alvarado-Fernandez, Maria
    Vazquez-Real, Miguel
    Marcos Rodriguez, Jose Antonio
    Santana Martinez, Sara
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 280 - 280
12345